Opthea Posts A$339.9M Profit, Shifts Focus to LAM Treatment with OPT-302
Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.
- H1 2026 profit of A$339.9 million after DFA settlement reversal
- Strategic pivot to develop OPT-302 targeting rare lung disease LAM
- CEO transition with Chairman Jeremy Levin assuming leadership
- Strong cash position supports self-funded early development
- Company to seek shareholder approval for name change reflecting new focus
A Financial Rebound and Strategic Reset
Opthea Limited has delivered a remarkable financial turnaround in the half-year ended 31 December 2025, reporting a profit after tax of A$339.9 million compared to a loss of A$201.1 million in the prior corresponding period. This swing was largely driven by the derecognition of a Development Funding Agreement (DFA) liability following its settlement, which removed a significant financial burden from the company’s balance sheet.
Alongside this financial reset, Opthea has completed a comprehensive strategic review that has led to a decisive pivot away from its previous ophthalmology focus. The company is now concentrating its efforts on developing OPT-302, a biologic therapy aimed at treating Lymphangioleiomyomatosis (LAM), a rare and devastating lung disease that predominantly affects women of reproductive age.
Targeting a Rare Disease with High Unmet Need
LAM is characterised by progressive lung damage and limited treatment options, with current therapies often unable to halt disease progression. OPT-302 works by trapping key growth factors VEGF-C and VEGF-D, which are implicated in the abnormal lymphatic vessel remodelling central to LAM pathology. This mechanism complements existing mTOR inhibitor treatments, potentially offering a more comprehensive therapeutic approach.
Opthea’s leadership believes this focus aligns well with the company’s existing biologic development expertise, intellectual property portfolio, and safety data, while also leveraging a strong global network of specialist clinics and patient foundations. The company anticipates that OPT-302 may qualify for orphan drug designation, which could provide regulatory and commercial advantages.
Leadership and Operational Changes
In August 2025, Opthea’s CEO Dr Fred Guerard departed, with Executive Chairman Dr Jeremy Levin stepping in as CEO. This leadership consolidation accompanies a significant reduction in workforce and board size, reflecting a streamlined operational model focused on capital discipline and data-driven decision-making.
The company remains suspended on the ASX but is preparing for reinstatement in the first half of 2026. It also voluntarily delisted its American Depositary Shares from NASDAQ in November 2025, signalling a strategic realignment towards Australia, which is now the company’s functional and presentation currency base.
Financial Position and Future Outlook
Opthea ended the half-year with cash and cash equivalents of A$33.2 million, sufficient to self-fund the initial stages of the OPT-302 development program without near-term capital raises. The company has structured its LAM program around clear, staged milestones with go/no-go decision points to manage risk prudently.
Looking ahead, the Board plans to seek shareholder approval for a company name change to better reflect its new strategic direction. Engagement with the LAM community will be a priority to ensure patient-centric development and regulatory alignment.
Bottom Line?
Opthea’s bold pivot and financial reset set the stage for a high-stakes journey into rare disease therapy, with clinical and market milestones ahead.
Questions in the middle?
- How will Opthea’s clinical trial design address the unique challenges of LAM?
- What timeline does the company anticipate for regulatory approvals and potential orphan drug status?
- How will the ASX reinstatement impact investor confidence and share liquidity?
